Abstract: Fused polycyclic 2-aminopyrimidines of formula (1): ##STR1## wherein Ar is an optionally substituted aromatic or heteroaromatic group;X is a carbon or nitrogen atom;Y is a carbon or nitrogen atom;Z is a linker group;A together with X and Y forms an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group;and the salts, solvates, hydrates and N-oxides thereof are described. The compounds are potent and selective inhibitors of the protein tyrosine kinases p56.sup.lck and p59.sup.fyn and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56.sup.lck and/or p59.sup.fyn activity is believed to have a role.

Abstract: A circuit card connector that utilizes flexible circuitry includes an elongated base, a pair of cradle spring members supported on the base, and a pair of contact springs movably supported on the cradle spring members. The cradle spring members include a plurality of reset arms that extend upwardly therefrom into contact with the undersides of the flexible circuitry. The flexible circuitry includes an apertured ground plane layer spaced apart from and located beneath the signal face layer. The apertures in the ground plane layer increase its flexibility especially at the interconnection interfaces to increase the compliance of the connector.

Abstract: 2-Anilinopyrimidines, processes for their preparation, pharmaceutical compositions containing them, their use in medicine. In a preferred embodiment, the compounds have the general formula (1): ##STR1## wherein R.sup.1 is preferably methoxy; R.sup.2 and R.sup.3 are preferably methyl; R.sup.4 is preferably a hydrogen atom; R.sup.5 is a hydrogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R.sup.6 is a hydrogen or halogen atom or an amino (--NH.sub.2), substituted amino, nitro, carboxyl (--CO.sub.2 H), esterified carboxyl or --X.sup.1 R.sup.6a where X.sup.1 is a direct bond or a linker atom or group and R.sup.6a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; X is a direct bond or a linker atom or group; and R.sup.7 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group.

Abstract: Compounds of general formula (1) are described: ##STR1## wherein Ar is an optionally substituted aromatic or heteroaromatic group;X.sup.1 is an oxygen or sulphur atom;R.sup.1 is a hydrogen atom or a methyl group;R.sup.2 is a hydrogen atom or a group --Alk.sup.1 or --X.sup.2 Alk.sup.1 where Alk.sup.1 is an optionally substituted aliphatic or heteroaliphatic group and X.sup.2 is a --C(O)--, --C(S)--, or --S(O).sub.n group where n is an integer 1 or 2;R.sup.3 is a hydrogen atom or a group --Alk.sup.2, ?where Alk.sup.2 is as defined for Alk.sup.1 !, --X.sup.2 Alk.sup.2, --Ar.sup.1 ?where Ar.sup.1 is an optionally substituted aromatic or heteroaromatic group!, --Alk.sup.2 Ar.sup.1, or --X.sup.2 Alk.sup.2 Ar.sup.1 ;and the salts, solvates, hydrates and N-oxides thereof.The compounds are selective inhibitors of the protein tyrosine kinase p56.sup.lck and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56.sup.